Generate Biomedicines, Inc.
GENB
$15.64
$0.614.06%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Net Income | -28.28% | -47.41% | |||
| Total Depreciation and Amortization | -2.95% | -4.13% | |||
| Total Amortization of Deferred Charges | -- | -- | |||
| Total Other Non-Cash Items | 513.68% | 232.86% | |||
| Change in Net Operating Assets | -226.69% | -75.76% | |||
| Cash from Operations | -18.85% | -51.17% | |||
| Capital Expenditure | -505.84% | -403.46% | |||
| Sale of Property, Plant, and Equipment | -- | -- | |||
| Cash Acquisitions | -- | -- | |||
| Divestitures | -- | -- | |||
| Other Investing Activities | 302.46% | -435.79% | |||
| Cash from Investing | 295.17% | -444.14% | |||
| Total Debt Issued | -- | -- | |||
| Total Debt Repaid | 58.90% | 57.86% | |||
| Issuance of Common Stock | 168.83% | 77,023.40% | |||
| Repurchase of Common Stock | -- | -- | |||
| Issuance of Preferred Stock | -- | -- | |||
| Repurchase of Preferred Stock | -- | -- | |||
| Total Dividends Paid | -- | -- | |||
| Other Financing Activities | -100.00% | 900.00% | |||
| Cash from Financing | -120.15% | 1,742.86% | |||
| Foreign Exchange rate Adjustments | -- | -- | |||
| Miscellaneous Cash Flow Adjustments | -- | -- | |||
| Net Change in Cash | 61.85% | -10.13% | |||